Dr. Kolibaba on Mechanism of Action With Entospletinib in MCL | OncLive

Dr. Kolibaba on Mechanism of Action With Entospletinib in MCL

December 23, 2016

Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses the mechanism of action with entospletinib (GS-9973) and its potential as a treatment for patients with mantle cell lymphoma (MCL).

Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses the mechanism of action with entospletinib (GS-9973) and its potential as a treatment for patients with mantle cell lymphoma (MCL).

Entospletinib is a specific tyrosine inhibitor directed against (Syk), which is found to be active in many B-cell malignancies. This phase II study explored the agent across several B-cell malignancies, Kolibaba adds. Results of the MCL cohort, in which entospletinib which showed encouraging activity, were presented at the 2016 ASH Annual Meeting.

Researchers were very excited that a specific inhibitor of Syk was developed in the hopes that there might be efficacy and decreased toxicity. In this study, it was found that the agent was very well tolerated, Kolibaba adds.


x